Exhibit
99.1
EUDA
Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
SINGAPORE,
April 28, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”),
a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen
Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under
the 2025 Shenzhen Key Industry R&D Program.
The
Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial
development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under the supervision of
the Shenzhen Science and Technology Innovation Bureau (the “Bureau”). Following this approval, it is expected that the Bureau
may provide funding of up to approximately US$434,688 to support Shenzhen Inno’s “Key Technology Development of TCR-T Therapy
for Solid Tumors” project.
Pursuant
to a non-exclusive distribution arrangement, EUDA holds the rights to market and sell selected immunotherapies provided by Shenzhen Inno
to customers in Malaysia through its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Shenzhen
Inno’s Project Highlights & Scientific Focus
Shenzhen
Inno’s project focuses on the development of TCR-T cell therapies targeting solid tumors, an area of oncology that remains challenging
due to tumor heterogeneity and immune resistance.
●
Broad Target Coverage
Development of HLA-restricted epitopes targeting cancer-testis antigens with high expression across multiple
tumor types, with an initial focus on epitopes prevalent within the Chinese population.
●
AI-Driven Antigen Screening Platform
Utilization of high-throughput, AI-driven screening technologies to identify optimized TCR
candidates, in collaboration with leading research institutions including Shenzhen Bay Laboratory and the Shenzhen Institutes of Advanced
Technology under the Chinese Academy of Sciences.
●
Enhanced Cellular Engineering
Engineering of TCR-T cells designed to address key therapeutic limitations such as T-cell exhaustion
and limited persistence within the tumor microenvironment, with the objective of improving durability and efficacy.
●
Integrated Research and Clinical Framework
Collaboration with Shenzhen People’s Hospital to conduct exploratory clinical
studies evaluating safety and efficacy, alongside the development of standardized yet adaptable manufacturing processes for advanced
cellular therapies.
Strategic
Relevance to EUDA
The
approval of this project under a government-led program reflects continued progress in cellular immunotherapy development and aligns
with EUDA’s strategy to expand access to advanced treatment modalities through its commercial channels. This development provides
EUDA with continued exposure to next-generation T-cell therapies within its existing distribution scope. Through its distribution framework,
EUDA facilitates the delivery of science-driven healthcare solutions to its customers while maintaining a commercially focused approach
to advanced therapies.
Mr.
Alfred Lim, Chief Executive Officer of EUDA, commented:
“The
approval of this project reflects ongoing progress in advanced cellular therapy research. Developments in areas such as TCR-T therapy
continue to expand the scope of future treatment possibilities, and EUDA remains focused on identifying opportunities to bring clinically
relevant innovations to our customers.”
About
EUDA Health Holdings Limited
EUDA
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia
and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing
longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing
significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed
health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive,
longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking
Statements
Certain
statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations
of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may
include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability
to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings
and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based
on currently available information. Estimates and projections contained herein have been prepared by management and involve significant
elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied,
is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be
relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these
forward-looking statements.
This
press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an
offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information
from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to
be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice.
Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not
undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of
unanticipated events.
Christensen
Advisory
Christian
Arnell
Phone:
+ 852 9040 0621
Email:
christian.arnell@christensencomms.com
